← All trials
NCT06320067
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 11, 2024
- Primary completion
- Apr 30, 2031
- Completion date
- Mar 31, 2034
- First posted
- Mar 20, 2024
- Last posted
- Aug 9, 2024
- Enrollment
- 8000
- Arms / groups
- 6 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of LondonLead sponsor
- Janssen Pharmaceutica NVCollaborator
- Medical Research CouncilOfficial
- University of LondonOfficial
- Cancer Research UKCollaborator
- NovartisCollaborator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.